MedTrace Logo

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

NCT02805556 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-07-21

No results posted yet for this study

Summary

A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-663068

Single oral dose of BMS-663068

DRUG

BMS-626529

Single intravenous dose of \[13C\]BMS 626529

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-15
Primary Completion
2016-05-05
Completion
2016-05-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02805556 on ClinicalTrials.gov